Back to Results
First PageMeta Content
Dosage forms / Non-steroidal anti-inflammatory drugs / Morphinans / Alcohols / Aspirin / Salicylates / Tablet / Dextropropoxyphene / Hydromorphone / Chemistry / Pharmacology / Medicine


New Zealand Consumer Medicine Information PERSANTIN® PL 150 mg Sustained-release capsules PERSANTIN® 25 mg tablets
Add to Reading List

Document Date: 2015-07-14 21:43:21


Open Document

File Size: 57,34 KB

Share Result on Facebook

Company

BOEHRINGER INGELHEIM (N.Z.) LIMITED / /

Country

Germany / France / New Zealand / /

IndustryTerm

treatment of high blood pressure / treatment of myasthenia gravis / machinery / /

MedicalCondition

allergic reaction / flushing / Headache / hives / nausea / Skin rash / heart disease / thrombocytopenia / blood clots / Lapp lactase deficiency / Low blood pressure / rare hereditary conditions / blister / heart failure / heart attack / allergic reactions / circulation causing chest pain / Muscle aches / restlessness / high blood pressure / dizziness / e.g. angina / fructose intolerance / such an allergy / severe muscle disease / lightheadedness / myasthenia gravis / /

MedicalTreatment

surgery / /

Organization

Poisons Information Centre / /

/

Position

pharmacist / /

Product

talc / PERSANTIN tablets / Storage Leave / Dipyridamole / Sustained-release capsules / Each PERSANTIN 25 / adenosine / /

SocialTag